AU2002326751A1 - Immunoglobulin e vaccines and methods of use thereof - Google Patents

Immunoglobulin e vaccines and methods of use thereof

Info

Publication number
AU2002326751A1
AU2002326751A1 AU2002326751A AU2002326751A AU2002326751A1 AU 2002326751 A1 AU2002326751 A1 AU 2002326751A1 AU 2002326751 A AU2002326751 A AU 2002326751A AU 2002326751 A AU2002326751 A AU 2002326751A AU 2002326751 A1 AU2002326751 A1 AU 2002326751A1
Authority
AU
Australia
Prior art keywords
vaccines
immunoglobulin
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002326751A
Inventor
Theresa Barankiewicz
Swey-Shen Alex Chen
Zhong Chen
Yong-Min Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGE THERAPEUTICS Inc
Original Assignee
IGE THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGE THERAPEUTICS Inc filed Critical IGE THERAPEUTICS Inc
Publication of AU2002326751A1 publication Critical patent/AU2002326751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2002326751A 2001-08-13 2002-08-08 Immunoglobulin e vaccines and methods of use thereof Abandoned AU2002326751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31212001P 2001-08-13 2001-08-13
US60/312,120 2001-08-13
PCT/US2002/026986 WO2003015716A2 (en) 2001-08-13 2002-08-08 Immunoglobulin e vaccines and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2002326751A1 true AU2002326751A1 (en) 2003-03-03

Family

ID=23209966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002326751A Abandoned AU2002326751A1 (en) 2001-08-13 2002-08-08 Immunoglobulin e vaccines and methods of use thereof

Country Status (4)

Country Link
US (1) US7604955B2 (en)
EP (1) EP1497654A4 (en)
AU (1) AU2002326751A1 (en)
WO (1) WO2003015716A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
JP2004500405A (en) 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア Compositions and methods for enhancing the immunogenicity of an antigen
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
DE60233231D1 (en) * 2001-05-15 2009-09-17 Ortho Mcneil Janssen Pharm EX-VIVO-PRIMING FOR THE PRODUCTION OF CD40-LIGAND SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF AUTOIMMUN AND ALLERGIC DISEASES
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP1504102A2 (en) 2002-05-21 2005-02-09 Resistentia Pharmaceuticals AB Chimeric ige polypeptides and host cells
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
KR100541654B1 (en) * 2003-12-02 2006-01-12 삼성전자주식회사 Wiring substrate and solid-state imaging apparatus using thereof
US20080241069A1 (en) * 2006-08-04 2008-10-02 Yvonne Paterson Methods and compositions for treating IgE-mediated diseases
CN104962616B (en) * 2015-06-05 2018-05-01 安徽农业大学 The screening technique of Anhui's local pig kind disease resistance trait candidate genetic mark
CN105039518B (en) * 2015-06-05 2018-07-17 安徽农业大学 The screening technique of Anhui's local pig kind weanling pig premunition candidate genetic label

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US5180805A (en) * 1986-07-02 1993-01-19 Research Corporation Limited Polypeptide competitor for immunoglobulin E
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5428133A (en) * 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
ES2082850T3 (en) 1989-02-24 1996-04-01 Univ California GENETICALLY PREPARED IMMUNOGLOBULINS.
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
SE9102808L (en) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo VACCIN, HOW TO USE HUMAN USE, WILL BE INTENDED TO EFFECT THE SYMPTOMS OR PREVENT THE RISE OF IGE-MEDIATED ALLERGIC REACTIONS
ATE301201T1 (en) * 1993-06-07 2005-08-15 Vical Inc PLASMIDS USABLE FOR GENE THERAPY
EP0811016A1 (en) 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
CA2203165A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9526599D0 (en) * 1995-12-28 1996-02-28 Sandoz Ltd Elisa test system
WO1997031948A1 (en) 1996-03-01 1997-09-04 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6110889A (en) * 1996-06-14 2000-08-29 Board Of Regents, The University Of Texas System Peptide tumor cell growth inhibitors
US6025485A (en) * 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
US6406706B1 (en) 1996-11-05 2002-06-18 Haque, Inc. Use of α- and β-santalols major constituents of sandal wood oil, in the treatment of warts, skin blemishes and other viral-induced tumors
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
EP1127076A2 (en) 1998-11-05 2001-08-29 Heska Corporation Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
WO2001069253A2 (en) 2000-03-15 2001-09-20 Heska Corporation 3d model of an fc epsilon receptor alpha chain-ige fc region complex
EP1294886A2 (en) 2000-03-15 2003-03-26 Northwestern University THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IGE ANTIBODY AND USES THEREOF
JP2004508028A (en) * 2000-09-06 2004-03-18 ファーメクサ　エイ／エス Method for down-regulating IgE
AU2002214545B2 (en) 2000-09-26 2008-04-03 Genentech, Inc. IGE receptor antagonists
WO2002034287A2 (en) 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
DE60233231D1 (en) * 2001-05-15 2009-09-17 Ortho Mcneil Janssen Pharm EX-VIVO-PRIMING FOR THE PRODUCTION OF CD40-LIGAND SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF AUTOIMMUN AND ALLERGIC DISEASES

Also Published As

Publication number Publication date
WO2003015716A3 (en) 2004-11-04
US7604955B2 (en) 2009-10-20
EP1497654A2 (en) 2005-01-19
EP1497654A4 (en) 2006-06-07
WO2003015716A2 (en) 2003-02-27
US20030073142A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
IL157142A0 (en) Modified antibodies and methods of use
AU2002330943A1 (en) Immunomodulatory compounds and methods of use thereof
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2002327164A1 (en) Engineered tetravalent antibodies and methods of use
AU2002258790A1 (en) Novel microarrays and methods of use thereof
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
AU2002306768A1 (en) Expression profiles and methods of use
AU2002324775A1 (en) Architecture tool and methods of use
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002316118A1 (en) Nucleic acid-based compounds and methods of use thereof
AU2002359512A1 (en) Belts and methods of use thereof
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002365228A1 (en) Antigen panels and methods of using the same
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2002347464A1 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2002341828A1 (en) Enhanced proteins and methods for their use
EP1416889A4 (en) Small incision lens and method of use thereof
AU2002237432A1 (en) Complex element micro-array and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase